Study guide

6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy

Neonatal Pediatric Transport C-NPT

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The C-NPT Exam

About the C-NPT Exam: 2026 Format, Eligibility & Content Outline

2 Chapter 1: Transport Systems, Regulatory Framework & Legal Issues

1.1 Transport System Architecture, Accreditation (CAMTS) & Dispatch Triage 1.2 Regulatory & Legal Mandates: EMTALA, HIPAA, Consent & Documentation 1.3 Medical Direction, Scope of Practice & Ethical Considerations

3 Chapter 2: Safety, Communication, Crew Resource Management & Transport Environment

2.1 Crew Resource Management (CRM), Situational Awareness & Sterile Cockpit 2.2 Aircraft & Ground Ambulance Operations, Landing Zones & Vehicle Dynamics 2.3 Environmental Hazards, Weather Minimums & In-Flight Emergency Procedures 2.4 Communication in Transport: Peer Handoffs, Age-Appropriate Care, Families & Crew Stressors 2.5 Infection Control, PPE, Scene Safety & Disaster/Evacuation Planning

4 Chapter 3: Flight Physiology & Environmental Stressors

3.1 Physical Gas Laws & Transport Implications (Boyle, Dalton, Charles, Henry, Graham) 3.2 Altitude Hypoxia, Barometric Pressure Changes & Dysbarism 3.3 Acceleration Forces (G-forces), Vibration & Acoustic Stress in Transit 3.4 Thermoregulation Physics & Neutral Thermal Environment in Transit

5 Chapter 4: Invasive Procedures & Transport Monitoring

4.1 Advanced Airway Management & Endotracheal Intubation in Transit 4.2 Pleural Decompression (Needle Thoracostomy & Chest Tube Management) 4.3 Vascular Access: Umbilical Lines (UAC/UVC), Intraosseous (IO) & Arterial Lines

6 Chapter 5: Transport Equipment, Respiratory Physiology & Mechanical Ventilation

5.1 Transport Incubators (Isolettes), Thermal Control & Electrical/Gas Power Systems 5.2 Portable Ventilators & Modes (PC, VC, PRVC, High Frequency) 5.3 Gas Cylinder Duration Calculations, Oxygen Delivery & Inhaled Nitric Oxide (iNO) 5.4 Respiratory Physiology: Acid-Base Balance, Oxygenation, Lung Mechanics & Troubleshooting

7 Chapter 6: Transport Pharmacology, Resuscitation, Fluids & Electrolytes

6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone) 6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport 6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy 6.4 Resuscitation Protocols (NRP, PALS) & Shock Fluid Resuscitation 6.5 Antimicrobial Pharmacology in Neonatal & Pediatric Transport 6.6 Post-Resuscitation Care, Defibrillation & Cardioversion in Transit, ECMO Indications & the Transport-vs-Stay Decision 6.7 Fluid & Electrolyte Therapy Across the Ages: Maintenance, Dehydration, Fluid Overload & Electrolyte Emergencies

8 Chapter 7: Neonatal Respiratory Pathologies & Management

7.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency 7.2 Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN) 7.3 Transient Tachypnea (TTN), Neonatal Pneumothorax & Congenital Diaphragmatic Hernia (CDH) 7.4 Neonatal Upper Airway Anomalies, Aspiration, Pneumonia, Chronic Lung Disease & Respiratory Failure

9 Chapter 8: Neonatal Cardiovascular Critical Care

8.1 Ductal-Dependent Cyanotic Congenital Heart Defects (TGA, TOF, Tricuspid Atresia) 8.2 Ductal-Dependent Systemic Blood Flow Lesions (HLHS, Coarctation, Interrupted Arch) 8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care 8.4 Acyanotic Congenital Heart Lesions, Patent Ductus Arteriosus, Obstructed TAPVR & Neonatal Heart Failure

10 Chapter 9: Neonatal Neurological & Metabolic Crises

9.1 Hypoxic-Ischemic Encephalopathy (HIE) & Passive/Active Therapeutic Hypothermia 9.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH) 9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia 9.4 Subgaleal Hemorrhage, Neonatal Sepsis & Meningitis, and Perinatal Substance Exposure (NOWS)

11 Chapter 10: Neonatal Surgical Emergencies, Neural Tube Defects & ELBW Care

10.1 Abdominal Wall Defects (Gastroschisis vs. Omphalocele) & TEF/Esophageal Atresia 10.2 Necrotizing Enterocolitis (NEC), Malrotation with Volvulus & Intestinal Obstruction 10.3 Care of the Extremely Low Birth Weight (ELBW) Infant (<1000g) in Transit 10.4 Neural Tube Defects: Myelomeningocele, Encephalocele & Transport of the Newborn With an Open Spinal Defect

12 Chapter 11: Pediatric Respiratory Emergencies

11.1 Acute Upper Airway Obstruction (Croup, Epiglottitis, Bacterial Tracheitis, Foreign Body) 11.2 Lower Airway Crises: Status Asthmaticus & Severe Bronchiolitis 11.3 Pediatric Acute Respiratory Distress Syndrome (PARDS) & Severe Pneumonia

13 Chapter 12: Pediatric Shock & Cardiovascular Crises

12.1 Pathophysiology & Transport Management of Pediatric Septic Shock 12.2 Hypovolemic, Cardiogenic & Anaphylactic Shock in Children 12.3 Pediatric Cardiac Emergencies: SVT, Ventricular Arrhythmias & Myocarditis 12.4 Pediatric Cardiovascular Crises: Palliated Congenital Heart Disease, Pulmonary Hypertensive Crisis, Pericarditis & Tamponade, Hypertensive Emergency & Anterior Mediastinal Mass

14 Chapter 13: Pediatric Neurological Emergencies & Trauma

13.1 Status Epilepticus, Altered Mental Status & Meningitis/Encephalitis 13.2 Pediatric Traumatic Brain Injury (TBI) & Increased Intracranial Pressure (ICP) 13.3 Blunt/Penetrating Trauma, Spinal Motion Restriction & Thermal Burns 13.4 Non-Accidental Trauma, Smoke Inhalation (Carbon Monoxide & Cyanide) & Heat Illness

15 Chapter 14: Pediatric Toxicological, Environmental & Endocrine Emergencies

14.1 Common Pediatric Toxic Ingestions, Poisonings & Antidotes 14.2 Diabetic Ketoacidosis (DKA) & Environmental Emergencies (Submersion, Hypothermia) 14.3 Button Battery & Foreign-Body Ingestions, Bites & Envenomations, and Hazardous-Material Exposures

16 Chapter 15: Pediatric Metabolic & Hematologic Emergencies

15.1 Anemia, Sickle Cell Disease, Coagulopathies & Blood Product Administration 15.2 Oncologic Emergencies, Acute Kidney Injury & Pediatric Electrolyte Crises

6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy

Key Takeaways Explain This Topic AI

Prostaglandin E1 (alprostadil) is a life-saving continuous infusion that maintains patency of the ductus arteriosus in neonates with ductal-dependent cyanotic, systemic, or parallel congenital heart disease.

PGE1 is initiated at 0.05-0.1 mcg/kg/min and titrated down to the lowest effective maintenance rate (0.01-0.025 mcg/kg/min) once ductal patency is established, minimizing adverse drug effects.

Apnea occurs in 10% to 20% of neonates receiving PGE1, most commonly within the first 60 minutes or at higher doses; transport crews must maintain a low threshold for elective prophylactic intubation prior to aeromedical or long-distance transport.

Exogenous surfactant (poractant alfa, beractant, calfactant) restores alveolar surface tension and functional residual capacity in preterm RDS and severe meconium aspiration syndrome.

Surfactant administration triggers a rapid, dramatic improvement in pulmonary compliance within minutes; transport clinicians must immediately wean peak inspiratory pressures (PIP) or tidal volume, reassess PEEP, and wean FiO2 to prevent alveolar overdistension, barotrauma, and tension pneumothorax.

Last updated: September 2026

Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy

Two pharmacological interventions stand out as uniquely transformative in neonatal critical care transport: Prostaglandin E1 (Alprostadil) and Exogenous Surfactant Replacement . Both therapies target life-threatening neonatal pathophysiologies that can rapidly deteriorate inside an aircraft or mobile intensive care unit. Mastery of ductal physiology, surfactant kinematics, administration techniques, and post-delivery ventilator adjustments is essential for high-scoring C-NPT candidates.

Prostaglandin E1 (Alprostadil): Ductal Architecture & Mechanism

In fetal circulation, the ductus arteriosus (DA) shunts oxygenated blood from the pulmonary artery directly into the descending aorta, bypassing high-resistance fetal pulmonary vasculature. Following birth, exposure to high ambient oxygen tensions and the abrupt withdrawal of maternal circulating prostaglandins trigger smooth muscle constriction, functional ductal closure within 12–24 hours, and anatomical obliteration within 2–3 weeks.

Alprostadil (PGE1) is a synthetic prostaglandin identical to endogenous PGE 1 \text{PGE}_1 PGE 1 ​ . It binds to specific prostanoid EP receptors on ductal vascular smooth muscle, activating adenylyl cyclase, increasing intracellular cAMP, and driving calcium extrusion. This relaxes ductal smooth muscle, maintaining or re-establishing patency of the ductus arteriosus.

Clinical Classification of Ductal-Dependent Cardiac Lesions

Transport clinicians must identify when a neonate's survival depends entirely on maintaining a patent ductus arteriosus (PDA):

Ductal-Dependent Pulmonary Blood Flow (Cyanotic Lesions): Pulmonary blood flow is obstructed; deoxygenated blood cannot reach the lungs without right-to-left or aorta-to-pulmonary shunting across the PDA. Examples: Pulmonary Atresia, Critical Pulmonary Stenosis, Tricuspid Atresia, severe Tetralogy of Fallot.

Clinical Presentation: Severe, progressive central cyanosis unresponsive to 100% FiO 2 \text{FiO}_2 FiO 2 ​ (hyperoxia test negative: PaO 2 < 100 \text{PaO}_2 < 100 PaO 2 ​ < 100 mmHg).

Ductal-Dependent Systemic Blood Flow (Acyanotic / Obstructive Lesions): Systemic blood flow is mechanically obstructed; the systemic circulation relies on right-to-left shunting from the pulmonary artery across the PDA into the descending aorta. Examples: Hypoplastic Left Heart Syndrome (HLHS), Critical Aortic Coarctation, Interrupted Aortic Arch, Critical Aortic Stenosis.

Clinical Presentation: Gray, mottled skin, absent or diminished femoral pulses, differential blood pressures (>15–20 mmHg difference between upper and lower extremities), cardiogenic shock, severe metabolic acidosis, and anuria as the ductus constricts at 2–14 days of life.

Parallel Circulations (Mixing Dependent): Systemic and pulmonary circulations run in parallel loops rather than series. Example: Transposition of the Great Arteries (TGA).

Clinical Presentation: Profound cyanosis refractory to oxygen; survival requires bidirectional mixing at the atrial septum and PDA.

PGE1 Dosing, Titration & Administration Logistics

PGE1 has a very short half-life (5–10 minutes), with 70–80% cleared on first pass through the pulmonary vasculature. It requires a dedicated, continuous intravenous or intraosseous infusion.

Initial Resuscitation Dose: 0.05 to 0.1 mcg/kg/min . In a neonate presenting in fulminant ductal closure and shock, this dose rapidly re-opens the constricted ductus, typically producing noticeable improvement in arterial oxygen saturation, pulses, and blood pressure within 15–30 minutes.

Maintenance Titration: Once ductal patency and clinical stabilization are verified, the infusion rate must be titrated down to the lowest effective dose: 0.01 to 0.025 mcg/kg/min . Titrating downward minimizes systemic adverse effects during a prolonged transport.

Infusion Mechanics: PGE1 can be infused through a peripheral IV, umbilical venous catheter (UVC), or intraosseous (IO) line. It should run via a dedicated lumen with microbore tubing. Inadvertent line flushing must be strictly prevented; a sudden bolus can trigger immediate apnea and cardiovascular collapse.

PGE1 Adverse Effects & Transport Airway Contingencies

Adverse Effect Approximate Incidence Pathophysiological Mechanism Transport Management Strategy

Apnea 10% – 20% Central depression of the medullary respiratory center; dose-dependent Maintain low threshold for prophylactic elective intubation prior to transport departure. Have bag-mask resuscitator, suction, and appropriately sized ETT immediately available.

Hypotension & Flushing 15% – 25% Direct smooth muscle relaxation of systemic peripheral arterioles Peripheral cutaneous erythema is benign. For systemic hypotension, administer a cautious isotonic crystalloid bolus (10 mL/kg normal saline) and wean PGE1 to maintenance.

Hyperthermia 10% – 15% Prostaglandin-mediated alteration of hypothalamic thermoregulatory set-point High core temperatures (38.5–39.5°C) mimic sepsis. Differentiate from true infection; avoid overcooling; adjust isolette temperature down.

Seizure-Like Twitching 1% – 3% Cortical irritation / CNS excitation Differentiate jitteriness from true electrographic seizure activity; reduce infusion rate if clinically tolerated.

Deciding on Elective Intubation Before Transport

Apnea is the most hazardous complication of PGE1 during critical care transport. It occurs most frequently within the first 60 minutes of initiating therapy, especially at doses ≥ 0.05 \ge 0.05 ≥ 0.05 mcg/kg/min. In a cramped, vibrating aircraft cabin under night flying conditions, managing sudden neonatal apnea and unheralded bradycardia is exceptionally high-risk. Many programs strongly consider elective intubation before departure for infants on PGE1 who need air transport or a long ground transport, especially after a recent start or at higher doses. Observational studies show that many infants on low-dose PGE1 travel safely without intubation, so the decision weighs dose, apnea already observed, gestational age, and transport mode and duration. If intubation is withheld in a stable neonate on low maintenance dose (0.01 mcg/kg/min), the crew must maintain continuous capnography, pulse oximetry, and immediate airway equipment at the bedside.

Exogenous Surfactant Replacement Therapy

Pulmonary surfactant is an amphipathic complex of 90% lipids (primarily dipalmitoylphosphatidylcholine, DPPC) and 10% proteins (Surfactant Proteins A, B, C, and D) produced by type II alveolar pneumocytes. Surfactant reduces alveolar surface tension at low lung volumes, preventing end-expiratory alveolar collapse, stabilizing functional residual capacity (FRC), improving pulmonary compliance, and preventing non-cardiogenic pulmonary edema.

Transport Indications

Neonatal Respiratory Distress Syndrome (RDS): Primary surfactant deficiency in preterm infants (<34–35 weeks gestation).

Meconium Aspiration Syndrome (MAS): Secondary surfactant inactivation and chemical pneumonitis caused by free fatty acids, bile salts, and serum proteins.

Neonatal Pneumonia & Sepsis: Inflammatory exudates inactivating alveolar surfactant.

Surfactant Preparations & Dosing

Modern surfactant preparations are derived from animal lung extracts containing essential hydrophobic proteins SP-B and SP-C:

Poractant Alfa (Curosurf): Porcine lung extract. Highly concentrated, allowing smaller instillation volumes. Initial dose: 200 mg/kg (2.5 mL/kg) intratracheally. Subsequent doses: 100 mg/kg (1.25 mL/kg) every 12 hours if needed (max total 400 mg/kg).

Beractant (Survanta): Modified bovine lung extract. Dose: 100 mg/kg (4.0 mL/kg) intratracheally in 4 divided aliquots, repeated every 6 hours (up to 4 doses in 48 hours).

Calfactant (Infasurf): Calf lung extract. Dose: 105 mg/kg (3.0 mL/kg) intratracheally in 2 divided aliquots, repeated every 12 hours.

Administration Modalities: Traditional Catheter, INSURE & LISA

Traditional Catheter Instillation via ETT: The infant is intubated. Surfactant is warmed to room temperature and instilled directly into the trachea using a catheter inserted through a multi-access suction port or inline adapter while maintaining mechanical ventilation.

INSURE Method (INtubate - SURfactant - Extubate): The preterm neonate on non-invasive CPAP who develops worsening work of breathing is briefly intubated, receives surfactant, is gently ventilated for 5–15 minutes until stable, and is immediately extubated back to CPAP/NIPPV.

LISA / MIST (Less Invasive Surfactant Administration / Minimally Invasive Surfactant Therapy): Surfactant is administered to a spontaneously breathing infant maintained on CPAP via a thin vascular catheter or feeding tube threaded through the vocal cords under direct or video laryngoscopy, avoiding positive-pressure mechanical ventilation entirely.

Transport Consideration: LISA and rapid INSURE require highly controlled environments. For long-distance interfacility transport, if the infant requires surfactant at the referring facility, standard practice often involves securing the ETT for the duration of transport to prevent accidental extubation and decompensation in transit.

Post-Administration Pulmonary Hemodynamics & Ventilator Weaning

The most dangerous phase of surfactant therapy occurs in the 5 to 30 minutes following successful delivery . As surfactant spreads across the alveolar-air interface, alveolar surface tension drops precipitously, producing an immediate, dramatic improvement in dynamic pulmonary compliance.

The Barotrauma & Volutrauma Trap

If the transport clinician leaves mechanical ventilator settings unchanged, the sudden rise in compliance will cause delivered tidal volumes to surge uncontrollably (volutrauma). High peak inspiratory pressures (PIP) acting on compliant lungs deliver excessive shear stress, rapidly causing:

Pneumothorax and Pulmonary Interstitial Emphysema (PIE): Alveolar rupture into the pleural space.

Acute Hypocarbia ( PaCO 2 < 25 \text{PaCO}_2 < 25 PaCO 2 ​ < 25 –30 mmHg): Hyperventilation blows off carbon dioxide, causing profound cerebral vasoconstriction and predisposing the preterm infant to severe periventricular leukomalacia (PVL) and intraventricular hemorrhage (IVH).

Mandatory Action Post-Surfactant

Continuous bedside observation is mandatory immediately following instillation. As SpO2 rises and chest excursion increases, the clinician must rapidly wean PIP (or tidal volume), reassess PEEP, and titrate FiO2 downward to maintain target saturations and prevent air leak syndromes.

Loading diagram... PGE1 & Surfactant Transport Decision Pathway